Mucocutaneous Lesions in the Behcet Syndrome
Authors: Haluk Demiroglu
Journal: Annals of Internal Medicine (1998)

Letters15 November 1998Mucocutaneous Lesions in the Behcet SyndromeHaluk Demiroglu, MD, Suayib Yalcin, MD, and Yahya Buyukasik, MDHaluk Demiroglu, MDHacettepe University Medical School; Ankara, TurkeySearch for more papers by this author, Suayib Yalcin, MDHacettepe University Medical School; Ankara, TurkeySearch for more papers by this author, and Yahya Buyukasik, MDHacettepe University Medical School; Ankara, TurkeySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-10-199811150-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Hamuryudan and colleagues [1] present their successful results with thalidomide for the treatment of mucocutaneous lesions of the Behcet syndrome. In a previous study, we showed that benzathine penicillin, 1.2 million U once every 3 weeks, is also effective in the prevention and treatment of these lesions [2]. We suggest that controlled studies comparing the effects of benzathine penicillin and thalidomide be done in patients with mucocutaneous lesions dominating the clinical picture. If equally effective, penicillin is more advantageous than thalidomide because the former has fewer side effects and is safe, even in pregnant women.As Hamuryudan ...References1. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 128:443-50. Google Scholar2. Haznedaroglu IC, Demiroglu H, Ozcebe OI, Ozdemir O, Dundar SV. Benzathine penicillin in the prophylaxis and treatment of Behcet's disease [Abstract]. In: Boki KA, Drosos AA, Moutsopoulos HM, Tzioufas AG, Vlachoyiannopoulos PG, eds. Proceeding of the VIIth Mediterranean Congress of Rheumatology, 16-18 June 1994. Athens: Monduzzi Editore; 1994:185-8. Google Scholar3. Demiroglu H, Barista I, Dundar S. Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology. 1997; 104:701-5. Google Scholar4. Dundar S, Demiroglu H, Ozcebe OI, Ozdemir O, Caliskan S, Eldem B. Alpha interferon in Behcet's disease. Hematol Rev. 1996; 9:285-90. Google Scholar Author, Article, and Disclosure InformationAuthors: Haluk Demiroglu, MD; Suayib Yalcin, MD; Yahya Buyukasik, MDAffiliations: Hacettepe University Medical School; Ankara, Turkey PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe functional role of nuclear factor kappa-κB1 −94 ins/del ATTG promotor gene polymorphism in Behçet’s disease: an exploratory studyDoença de Behçet cursando com trombose de veia cava superiorBehçet’s disease: An update 15 November 1998Volume 129, Issue 10Page: 836KeywordsAdverse reactionsColchicineCyclophosphamideDrug therapyDrugsEye diseasesImmunosuppressivesLesionsPenicillinPregnancy ePublished: 15 August 2000 Issue Published: 15 November 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...